Objective The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-tosevere chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. Methods A patient-level simulation was developed to compare the costs and outcomes of IND/GLY versus SFC based on data from the LANTERN trial (NCT01709903). Monte-Carlo simulation methods were employed to follow individual patients over various time horizons. Population and efficacy inputs were derived from the LANTERN trial. Considering the payers' perspective, only direct costs were included. Costs and health outcomes were discounted annually at 3.0 % for all countries. Unit costs were taken from publically available sources with all costs converted to euros (€). The cost base year was 2015. Deterministic and probabilistic sensitivity analyses were undertaken to test the robustness of the model results. Results IND/GLY was found to be the dominant (more effective and less costly) treatment option compared with SFC in all four countries. The use of IND/GLY was associated with mean total cost savings per patient over a lifetime of €6202, €1974, €1611, and €220 in Canada, France, Italy, and Portugal, respectively. Sensitivity analysis showed that exacerbation rates had the largest impact on incremental costs and quality-adjusted life-years (QALYs). The probability of IND/GLY being cost effective was estimated to be [95 % for thresholds above €5000/QALY. Conclusion In patients with moderate to severe COPD, IND/GLY is likely to be a cost-effective treatment alternative compared with SFC.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by persistent airflow limitation that progresses over time. In 2010, COPD was identified as the third leading cause of deaths worldwide [1] . The prevalence rates of COPD in Europe were estimated to range between 2.1 and 26.1 % depending on the country, age group, and methods used [2] , corresponding to approximately 105 million persons (based on 2014 census figures). In Canada, the estimated prevalence rates of COPD among adults aged 40 years and older were 11.1, 7.3, and 0.9 % according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1, 2, and 3-4, respectively [3] , which corresponds to around 3.5 million persons. COPD imparts a significant economic burden on society and a substantial component of socioeconomic burden is related to the hospitalization for COPD exacerbations [4] [5] [6] . In Canada, the total costs of COPD hospitalizations were estimated at $1.5 billion Canadian dollars (Can$) per year [7] . In Europe, exacerbation-related costs are also considered to be the major cost drivers in COPD, which account for 50-75 % of the total COPD-related costs [8] . A previous exacerbation history is the best predictor of future exacerbations [9] [10] [11] [12] [13] , and exacerbation-related costs are the primary drivers of COPD-related costs [4] [5] [6] [7] [8] ; one of the main goals of managing COPD is therefore to reduce the frequency of exacerbations.
Though inhaled corticosteroids (ICS) in combination with a long-acting b 2 -adrenergic agonist (LABA) and/or a longacting muscarinic antagonist (LAMA) are recommended in group C and D patients [14] , evidence suggests that there is widespread prescribing of ICS in GOLD groups A and B, indicating non-adherence to international and national guidelines [15] [16] [17] [18] [19] [20] . Inappropriate use of ICS among patients in GOLD groups A and B can lead to increased healthcare costs [14, 15, 20, 21] , with an increased risk of adverse effects such as pneumonia, influenza, diabetes mellitus, and osteoporosis [14, [21] [22] [23] . These adverse effects increase morbidity, may result in hospitalizations, and eventually increase burden to the healthcare system. Therefore, new maintenance strategies are needed with more optimal clinical and economic values.
The dual bronchodilator indacaterol/glycopyrronium (IND/GLY), a combination of the LABA indacaterol and LAMA glycopyrronium, is approved for the maintenance treatment of COPD in Europe and Canada. The 2015 GOLD strategy recommends the use of a dual bronchodilator such as IND/GLY in patients who remain symptomatic on a single long-acting bronchodilator and who have a history of infrequent exacerbations [14] . On the other hand, the use of an ICS/LABA combination such as salmeterol/fluticasone combination (SFC) is recommended for patients with severe or very severe COPD and a history of repeated or severe exacerbations (i.e., GOLD groups C and D) [14] ; however, this combination is frequently prescribed in GOLD groups A and B in real-world settings (in up to one-third of patients) [15] [16] [17] [18] [19] [20] 24] . The LANTERN study (NCT01709903) population comprised of GOLD B (53 %) and D (47 %) patients based on modified Medical Research Council (mMRC) scores and lung function criteria. Given the large proportion of symptomatic moderate to severe COPD population categorized under GOLD B and D with a history of one or no exacerbation in the previous year, mMRC score C2, mean post-bronchodilator percentage predicted forced expiratory volume in 1 s (FEV 1 ) *52 %, and COPD assessment test score *14, monotherapy was not an appropriate comparator, and therefore it is postulated that comparison of a LABA/ LAMA versus an ICS/LABA may reflect the real-world cost effectiveness of medical therapy in our patient population.
Results from the LANTERN study in a broad COPD population with or without an exacerbation history (i.e., not excluding high-risk patients) demonstrated that IND/GLY significantly reduced the rate of moderate or severe exacerbations versus SFC [25] . This study also observed a lower incidence of pneumonia with IND/GLY (0.8 %) than with SFC (2.7 %). Recent data from the 1-year FLAME (NCT01782326) trial also confirms the superior efficacy of IND/GLY over SFC in terms of a reduced rate of all COPD exacerbations, improvement in trough FEV 1 , improved quality of life, and a decrease in the use of rescue medication among patients who had a history of at least one exacerbation during the previous year [26] . These results suggest that IND/GLY can be used as a new treatment option for patients with moderate to severe COPD without the potential associated ICS-related adverse events. This economic evaluation, therefore, aims to ascertain the impacts of improved clinical outcomes and particularly the reduced rate of COPD exacerbations observed in the LANTERN study on the healthcare costs in Canada and three countries in Europe (France, Italy, and Portugal).
Methods

Model Structure
A patient-level simulation was developed in Microsoft Office Ò Excel to compare the costs and outcomes of IND/ GLY versus SFC from the payers' perspective in Canada and three countries in Europe (France, Italy, and Portugal). The generated 100,000 patients progressed through the model employing Monte-Carlo simulation methods at each cycle. Single patients passed through the model, one at a time, progressing through clinical events based on his/her baseline characteristics and pre-defined probabilities of experiencing events (developing complications, and being symptomatic or progressing). These include the rate of FEV 1 decline, exacerbation, and pneumonia. A disease severity level was determined at each cycle. FEV 1 status was the representation of the patient's disease status in the model. A baseline FEV 1 score was simulated for each patient based on the baseline patient characteristics. A value was added to this based on the treatment the patient was assigned to and the treatment effect was applied only once. The patient's FEV 1 then declines over time at a rate reflective of the population described by Falaschetti and colleagues [27] . The decline in FEV 1 as calculated by the European Community for Steel and Coal (ECSC) (which uses an equation based on height and age) was used in the one-way sensitivity analysis [28] . As FEV 1 declines, patients move into GOLD states of increasing severity.
The parameters used in the model were described previously [29] . Though mentioned by Asukai and colleagues [29] , the Transition Dyspnoea Index and the St. George's Respiratory Questionnaire were not incorporated in the current model as change in these measures is specific for analysis of treatment switching and was not necessary for the current cost-effectiveness analysis. Pneumonia rates and costs were later added to the model as a relevant parameter due the inclusion of an ICS comparator and the established evidence of risk of pneumonia with ICS use [30] .
The model used cycle lengths of 6 months to match the clinical data as measured in the LANTERN trial. The time horizon of the model was lifetime, although results are also presented for 1, 3, 5, and 10 years. Costs and health outcomes were discounted annually at 3.0 % for all of the countries. The model structure is presented in Fig. 1 .
The model was validated previously using published trials as reported by Asukai and colleagues [29] . The model was tested to ensure that all calculations were correct and consistent with its specifications. Clinical predictability was tested by populating the model with four different datasets: one natural history of disease study [31] and three clinical trials [32] [33] [34] . The model was able to replicate the results of the published clinical trials and studies within reasonable ranges of acceptability.
Model Inputs
Clinical Data
The analyses incorporated clinical data from the LANTERN trial, a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group study, which aimed to assess the efficacy, safety, and tolerability of IND/GLY compared with SFC in patients with moderate to severe COPD with one moderate or severe exacerbation or none in the previous year [25] . The primary endpoint was to demonstrate non-inferiority of IND/GLY versus SFC in terms of post-dose trough FEV 1 after 26 weeks of treatment. Population and efficacy inputs used for the comparison of IND/GLY and SFC were derived from the LANTERN trial, as shown in Tables 1 and  2 . The improvement in FEV 1 was calculated for both IND/ GLY and SFC from LANTERN using the following equation (Eq. 1):
Mean FEV1 at 6 months À Mean FEV1 at baseline ð1Þ
The annualized rates of pneumonia-related hospitalization were derived from pneumonia rates reported at 6 months in the LANTERN study using the following equation (Eq. 2):
Annualized rate ¼
Number of events Person years ð2Þ
where person-years are equal to *N/2. The population inputs specific to the disease cohort for each of the individual countries were not used. Moreover, it was considered important to have consistency between the population inputs and the efficacy inputs used in the model.
Exacerbation rates (mild, moderate, and severe) for each treatment were recorded in the LANTERN study. Knowing that exacerbation history is the best predictor of future exacerbations [9] [10] [11] [12] [13] , supplementary information relating to this risk differential was incorporated. In particular, the baseline exacerbation rate was assumed to be 0.23 (95 % confidence interval [CI] 0.16-0.33) based on data from the LANTERN trial. This rate was representative of patients being treated with IND/GLY with no history of exacerbations. The link between exacerbation history and the likelihood of future exacerbations comes from the study conducted by Hurst and colleagues [9] , which derived odds ratios from the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study of 2.24 (95 % CI 1.17-4.47) and 5.72 (95 % CI 2.84-7.31), representing exacerbation histories of one exacerbation in the past year and two or more exacerbations in the past year, respectively. Data from LANTERN could not be used to estimate the impact of exacerbation history as the LANTERN trial excluded patients who were frequent exacerbators (i.e., more than one documented exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the previous year). To obtain the rate associated with patients being treated with SFC, the rate was adjusted using a rate ratio of 1.45 (95 % CI 1.10-1.97). This rate ratio was based on data from the LANTERN trial (pertaining to patients both with and without an exacerbation history) and was applied over the lifetime horizon of the model and to all severity stages. For the purpose of this cost-effectiveness model, it was assumed that continued treatment returns a continued treatment effect; this assumption was based on the results of the 1-year SPARK trial and FLAME trial [26, 35] . The same assumption was applied by Asukai and colleagues [29] . It was further assumed that the treatment effect observed in the LANTERN study was applicable to patients in the model who progressed on to experience more frequent exacerbations.
Costs and Resource Utilization
Considering the payers' perspective, only direct costs were included in the analyses. The components included under direct costs were COPD drugs, maintenance costs, and costs related to exacerbation events and pneumonia events. For exacerbations, two separate estimations were carried out in the model: (i) the probability of the occurrence of an exacerbation; and (ii) the probability that the exacerbation was severe versus non-severe. This second probability was dependent on the severity of the patient's GOLD state. These probabilities were derived from the pooled data of indacaterol trials [36] [37] [38] . Resource utilization parameters included in the cost-effectiveness analysis are presented in Table 3 . Data on resource use were collected from a German study and same utilization rates were applied to all the countries in order to obtain consistent and comparable cost estimates across countries [39] . Diagnosis-related group (DRG) data [40] [41] , national databases and websites [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] , and published literature [7, [57] [58] [59] [60] [61] [62] were sourced for cost inputs for each country. Country-specific unit costs were applied to the resource use data to calculate the costs in euros as shown in the Table 4 . Country-specific aggregated costs for maintenance and adverse events are also Table 5 . All unit costs were inflated to January 2015 values [63] . For Canada, exchange rate used was €1 = Can$1.4671 [64].
Utility Data
Patient characteristics from the LANTERN trial were used to calculate utilities at each cycle. These were calculated based on the regression method published by Rutten-van Mölken et al. [65] and is also described by Price et al. [66] .
Inputs for the regression model were provided from within the model where possible (sex, FEV 1 ) and were assumed from an observational study (ECLIPSE) [9] where not available. The following regression equation was used to calculate utility value at each cycle (Eq. where BMI is the body mass index. The model did not include disutilities for exacerbations.
Mortality Data
COPD mortality rates were calculated using general population mortality rates from each of the included countries [67] [68] [69] [70] and applying a hazard ratio of 1.02 (based on the OLIN [Obstructive Lung Disease in Northern Sweden] COPD study) which describes the increased risk of death associated with a decline in FEV 1 [71] . This hazard ratio was adjusted by the predicted decline in FEV 1 for an individual patient [27] , using the following equation (Eq. 4):
Probability of death ¼ ðgeneral population risk for the appropriate age and sexÞ Â 1:02^ðthe decline inFEV 1 percentage predictedÞ
Exacerbations themselves, in fact, did not affect mortality in this model. Both the rate of exacerbations and COPDrelated mortality rate were based on FEV 1 status.
Model Outputs
Three categories of outputs were produced: clinical, cost, and cost effectiveness. Cost-effectiveness scatter plots and cost-effectiveness acceptability curves (CEACs) were generated from the probabilistically simulated outputs. Number needed to treat (NNT) and number needed to harm (NNH) were estimated for exacerbation and pneumonia, respectively.
Sensitivity Analysis
The model was tested for robustness by one-way deterministic sensitivity analysis conducted for a cohort of 100,000 patients. The following parameters were varied to analyze the impact of changes on the incremental cost and incremental quality-adjusted life-years (QALYs):
• Annual rate of exacerbations associated with IND/GLY and SFC, which were ranged between the lower and upper limit of their 95 % CI.
• Exacerbation rate ratio of IND/GLY and SFC, which were ranged between the lower and upper limit of their 95 % CI. 
ICUR Dominant
ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio, QALYs quality-adjusted lifeyears
• Severe exacerbation proportion increased and decreased by 25 %.
• IND/GLY and SFC drug costs increased and decreased by 25 %.
• Discounting rates, which were varied from 0 % to 2.5, 3.5, 4, 5, 7, and 10 %, for both costs and effects.
• Pneumonia costs, maintenance costs, exacerbation costs, and drug costs increased and decreased by 25 %.
• COPD severity: only moderate, only severe, only very severe.
• GOLD distribution source-taken from the ILLUMI-NATE trial [72] .
• FEV 1 benefit with IND/GLY and SFC, which ranged between the lower and upper limit of their 95 % CI.
• Deterioration in lung function source-ECSC.
To account for the uncertainty around the estimated incremental cost-effectiveness ratio (ICER) values, probabilistic sensitivity analysis (PSA) was run using 10,000 patients and 1000 cohorts (where the model parameters associated with each cohort were sampled probabilistically). Gamma distributions were fitted to aggregated cost parameters; a log-Normal distribution was fitted to exacerbation, pneumonia parameters and mortality; and, finally, Normal distributions were fitted to utilities and treatment efficacy (FEV 1 ).
A convergence analysis was carried out to validate the number of simulations used.
Results
Less costs and better outcomes made IND/GLY treatment a dominant strategy in the base-case analysis for Canada, France, Italy, and Portugal over 1, 3, 5, and 10 years and the lifetime horizon (Table 6 ). With the use of IND/GLY compared with SFC, costs savings per patient occurred for maintenance costs, non-severe exacerbation costs, severe exacerbation costs, pneumonia costs, and total costs across all the countries (Fig. 2) .
Results from the one-way sensitivity analyses for France are presented in tornado diagrams (Figs. 3, 4 ). The variables with the largest effect on the incremental costs were exacerbation rates (annual rates and rate ratio) and drug costs of IND/GLY and SFC, while exacerbation rates and discount rates had the largest impact on incremental QALYs. Figure 5 presents the cost-effectiveness scatter plots which show that IND/GLY was dominant over SFC in 99.4, 96.6, 99.6, and 75.3 % of the simulations in Canada, France, Italy, and Portugal, respectively. CEACs were constructed for the four countries to understand the relationship between the willingness-to-pay (WTP) threshold and the probability of being cost effective at a given threshold (Fig. 6) . In Canada, France, Italy, and Portugal, the probability of IND/GLY being cost effective is [95 % for all thresholds above €5000/QALY. Figure 7 illustrates the incremental cost-utility ratio sensitivity according to IND/GLY and SFC price changes within the Canadian and French context. In Canada, IND/ GLY would still be dominant at SFC price over €1.35, which would correspond to a 57 % decline of the current SFC price, while the IND/GLY price could reach €3.56, i.e., a price increase of 94 %, and still be dominant over SFC. Similarly for France, IND/GLY would still be dominant at SFC price over €0.85, which would correspond to a 35 % decline of the current SFC price, while the IND/GLY price could reach €1.95, i.e., a price increase of 40 %, and still be dominant over SFC.
Based on the LANTERN study, the NNH for pneumonia was estimated to be 52.53, i.e., for every 52 people treated over 6 months with SFC rather than IND/GLY, on average, one will suffer a case of pneumonia. Again, the NNT to prevent one moderate or severe exacerbation was estimated to be 12.98, i.e., for every 13 people treated over 6 months with IND/GLY rather than SFC, on average, one less will suffer a case of exacerbation. The results of the convergence analysis showed balance of model accuracy and efficiency at around 4000 simulations, with minimal Monte-Carlo error thereafter.
Discussion
GOLD guidelines recommend the addition of ICS to LABAs for symptomatic patients with severe or very severe airflow limitation (group C and D) and/or those with two or more exacerbations per year requiring systemic corticosteroids with or without antibiotics as well as patients with one or more hospitalization per year for exacerbation [14] . However, evidence suggests that the majority of patients are placed on ICS due to impaired lung function and symptoms rather than the frequency of exacerbations [73] . The inappropriate use of ICS is not only documented in GOLD groups A and B but a significant over-utilization is also seen among patients falling in groups C and D with no history of exacerbations [15] [16] [17] [18] [19] [20] . Data from the LANTERN study suggest that IND/GLY is more effective than SFC in patients with one or no exacerbations per year, which represents over 80 % of patients with COPD [16, 25] . This is also a very important group (GOLD C and D with one exacerbation per year without hospitalization) as many patients with COPD fall in this category and prescribing IND/GLY instead of an ICS-containing combination will benefit both patients and payers. This analysis evaluated the cost effectiveness of IND/ GLY versus SFC in patients with moderate to severe COPD and a history of one or no exacerbations in the previous year. The payer's perspective was taken using unit costs from Canada, France, Italy, and Portugal. Both IND/ GLY and SFC are reimbursed and used in the maintenance treatment of COPD in these countries. By utilizing the clinical findings from the LANTERN trial, this analysis demonstrated that IND/GLY was more clinically effective and less costly than SFC in Canada, France, Italy, and Portugal over 1, 3, 5, and 10 years, and the lifetime horizon, thus indicating both immediate and long-term benefits of IND/GLY compared with SFC. IND/GLY was associated with cost savings along with efficacy and safety benefits when compared with SFC. Large differences in cost savings were observed in exacerbations costs and pneumonia costs, highlighting the importance of use of appropriate medication in patients with COPD, particularly in those among whom inappropriate and off-label use of ICS have been observed in clinical settings [15] [16] [17] [18] [19] [20] . NNT analysis supported the use of IND/GLY in causing fewer exacerbations and pneumonia events than SFC.
The probability of IND/GLY being cost effective was estimated to be [95 % for WTP thresholds above €5000/ QALY in all of the healthcare settings. Price sensitivity analyses demonstrated that IND/GLY would remain cost effective versus SFC even if large price changes occurred (increasing the price of IND/GLY up to 94.5 and 40.3 % or decreasing the price of SFC up to 57.0 and 35.1 % of the current values in Canada and France, respectively).
To the best of our knowledge, this study is the first to assess the cost effectiveness of IND/GLY versus SFC in a broad COPD population, i.e., patients with moderate to severe COPD with a history of one or no exacerbations in the previous year, using data from the LANTERN trial. However, the following limitations need to be considered when interpreting the results. First, the analysis was based on the 26-week LANTERN study, which was not powered for measuring exacerbations. Despite this limitation, an improvement in exacerbation rates was seen with IND/ GLY compared with SFC. Additionally, a post hoc subgroup analysis of the LANTERN study in those patients with a history of moderate or severe exacerbations at baseline supported the reduction in risk of exacerbation with IND/GLY compared with SFC. Though the LAN-TERN trial included a population with less severe exacerbations, the results are consistent with the 1-year FLAME trial which included a COPD population with more severe exacerbations. Second, though the LANTERN study population represents the majority of patients with COPD, the population did not include a full range of COPD severities (such as patients who were frequent exacerbators). Future research is needed in which the effect of IND/GLY should be compared with that of SFC in patients with very severe COPD. Third, correlation might have been better established by deriving the variance-covariance matrix from sources other than a single clinical trial. Fourth, the present model incorporated the exacerbation history, based on available data, in assessing the likelihood of future exacerbation events to improve the accuracy of the estimates. However, a more robust analysis could use a number of risk factors as predictors within a risk model to link exacerbation history to the likelihood of future exacerbations. Further, the link between exacerbation history and the likelihood of future exacerbations was derived from the ECLIPSE study, which included both exacerbators and non-exacerbators. It was assumed that the treatment effect observed in the LANTERN study is applicable to those who progressed on to experience more frequent exacerbations. Fifth, the estimation of the probability that the exacerbation was severe or non-severe was derived from the pooled data of monotherapy trials. Last, resource utilization rates were taken from a German study and the same utilization rates were applied to all of the countries as it was considered that utilization rates should be reasonably consistent across these countries.
It is also important to mention that this analysis was based on a randomized controlled trial, which included a pre-selected patient population with a constrained and intensive ecology of care. Comprehensive assessment of IND/GLY requires evaluation of data from real-life studies which include a broader patient population with various comorbidities and lifestyle factors.
Previously conducted cost-effectiveness analyses also demonstrated that IND/GLY provided better clinical outcomes and lower costs than SFC as the maintenance treatment of COPD in Swedish and Greek healthcare settings [66, 74] . These analyses were based on the clinical results from ILLUMINATE trial, which demonstrated that IND/GLY compared with SFC delayed the time to first exacerbation in patients with moderate to severe COPD with no history of exacerbations. The current analysis, however, explored the economic value in light of additional data from LANTERN study that was conducted in a broad COPD population.
There are no other studies published on this comparison. Nevertheless, various cost-effectiveness studies have been published that support the efficient use of other dual bronchodilators in patients with COPD compared with monotherapies [75] [76] [77] . IND/GLY was also found to be a dominant (more effective and less costly) treatment strategy when compared with tiotropium [74] .
Conclusion
IND/GLY compared with SFC improved clinical outcomes and was cost saving in patients with moderate to severe COPD and a history of one or no exacerbations in the previous year. Optimal utilization of IND/GLY may reduce the economic burden of COPD in Canada, France, Italy, and Portugal. Sensitivity analysis showed that exacerbation rates had the largest impact on incremental costs and QALYs. The probability of IND/GLY being cost effective was estimated to be [95 % for thresholds above €5000/ QALY.
